Atypical adenomatous hyperplasia (adenosis) of the prostate: DNA ploidy analysis and immunophenotype

International Journal of Surgical Pathology

Volumn 13, Issue 2, 2005, Pages 167-173

  Lopez Beltran, Antonio ^a   Qian, Junqi ^b   Montironi, Rodolfo ^c   Luque, Rafael J ^a   Bostwick, David G ^b  

^a Universidad de Cordoba   (Spain)

^b BOSTWICK LABORATORIES   (United States)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Adenosis; Atypical adenomatous hyperplasia; DNA ploidy; ki67 MIB1; Prostate cancer

Indexed keywords

BLOOD CLOTTING FACTOR 8; CHROMOGRANIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KERATIN; MONOCLONAL ANTIBODY KI 67; PROTEIN BCL 2;

ADENOCARCINOMA; ARTICLE; BASAL CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DIPLOIDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; MICROVASCULATURE; NODULAR HYPERPLASIA; PLOIDY; PRIORITY JOURNAL; PROSTATE ADENOMA; PROSTATECTOMY;

ADENOCARCINOMA; AGED; DNA, NEOPLASM; HUMANS; IMAGE CYTOMETRY; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PHENOTYPE; PLOIDIES; PROSTATIC DISEASES; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 18144377798     PISSN: 10668969     EISSN: None     Source Type: Journal    
DOI: 10.1177/106689690501300207     Document Type: Article

References (37)

1. Bostwick DG, Srigley J, Grignon D, Maksem J, Humphrey P, van der Kwast TH, Bose D, Harrison J, Young RH. Atypical adenomatous hyperplasia of the prostate: Morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol 24:819-832, 1993
2. Bostwick DG, Algaba F, Amin MB, Ayala A, Eble J, Goldstein N, Helpap B, Humphrey P, Grignon D, Jones EC. Consensus statement on terminology.- Recommendation to use atypical adenomatous hyperplasia in place of adenosis of the prostate. Am J Surg Pathol 18:1069-1070, 1994
3. Bostwick DG, Qian J. Atypical adenomatous hyperplasia of the prostate. Relationship with carcinoma in 217 whole-mount radical prostatectomies. Am J Surg Pathol 19:506-518, 1995
4. Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP. The association of benign prostatic hyperplasia and cancer of the prostate Cancer 70:291-301, 1992
5. Lopez-Beltran A, Artacho-Perula E, Luque-Barona RJ, Roldan-Villalobos R. Nuclear volume estimates in prostatic atypical adenomatous hyperplasia. Anal Quant Cytol Histol 22:438-444, 2000
6. Montironi R, Bartels PH, Hamilton PW, Thompson D. Atypical adenomatous hyperplasia (adenosis) of the prostate: Development of a Bayesian belief network for its distinction from well-differentiated adenocarcinoma. Hum Pathol 27:396-407, 1996
7. Montironi R, Mazzucchelli R, Scarpelli M. Precancerous lesions and conditions of the prostate: From morphological and biological characterization to chemoprevention. Ann N Y Acad Sci 963:169-184, 2002
8. Algaba F, Epstein JI, Fabus G, Helpap B, Nagle RB, Polito M. Working standards in prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Pathol Res Pract 191:836-837, 1995
9. Brawn PN. Adenosis of the prostate: A dysplastic lesion that can be confused with prostate adenocarcinoma. Cancer 49:826-833, 1982
10. Luque RJ, Lopez-Beltran A, Perez-Seoane C, Suzigan S. Sclerosing adenosis of the prostate. Histologic features in needle biopsy specimens. Arch Pathol Lab Med 127:14-16, 2003
11. Muezzinoglu B, Erdamar S, Chakraborty S, Wheeler TM. Verumontanum mucosal gland hyperplasia is associated with atypical adenomatous hyperplasia of the prostate. Arch Pathol Lab Med 125:358-360, 2001
12. Grignon DJ, Sakr WA. Atypical adenomatous hyperplasia of the prostate: A critical review. Eur Urol 30:206-211, 1996
13. Thorson P, Humphrey PA. Minimal adenocarcinoma in prostate needle biopsy tissue. Am J Clin Pathol 114:896-909, 2000
14. Helpap B. The biological significance of atypical hyperplasia of the prostate. Virchows Arch A Pathol Anat Histol 387:307-317, 1980
15. Helpap BG, Bostwick DG, Montironi R. The significance of atypical adenomatous hyperplasia and prostatic intraepithelial neoplasia for the development of prostate carcinoma. An update. Virchows Arch 426:425-434, 1995
16. Kovi J. Microscopic differential diagnosis of small acinar adenocarcinoma of prostate. Pathol Annu 20:157-196, 1985
17. Bostwick DG, Chang L. Overdiagnosis of prostatic adenocarcinoma. Semin Urol Oncol 17:199-205, 1999
18. Cheng L, Shan A, Cheville JC, Qian J, Bostwick DG. Atypical adenomatous hyperplasia of the prostate: A premalignant lesion? Cancer Res 58:389-391, 1998
19. Doll JA, Zhu X, Furman J, Kaleem Z, Torres C, Humphrey PA, Donis-Keller H. Genetic analysis of prostatic atypical adenomatous hyperplasia (adenosis). Am J Pathol 155:967-971, 1999
20. Molinie V, Fromont G, Sibony M, Vieillefond A, Vassiliu V, Cochand-Priollet B, Herve JM, Lebret T, Baglin AC. Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate. Mod Pathol 17:1180-1190, 2004
21. Montironi R, Scarpelli M, Lopez Beltran A. Carcinoma of the prostate: Inherited susceptibility, somatic gene defects and androgen receptors. Virchows Arch 444:503-508, 2004
22. Srigley JR. Benign mimickers of prostatic adenocarcinoma. Mod Pathol 17:328-348, 2004
23. Yang XJ, Wu CL, Woda BA, Dresser K, Tretiakova M, Fanger GR, Jiang Z. Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 26:921-925, 2002
24. McNeal JE. Origin and development of carcinoma in the prostate. Cancer 23:24-34, 1969
25. Kunju LP, Rubin MA, Chinnaiyan AM, Shah RB. Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. Am J Clin Pathol 120:737-745, 2003
26. Qian J, Jenkins RB, Bostwick DG. Chromosomal anomalies in atypical adenomatous hyperplasia and carcinoma of the prostate using fluorescence in situ hybridization. Urology 46:837-842, 1995
27. Haussler O, Epstein JI, Amin MB, Helitz PU, Hailemariam S. Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer. Hum Pathol 30:1077-1086, 1999
28. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (eds). AJCC Cancer staging manual. New York, Berlin, Heidelberg, Springer-Verlag, pp. 309-316, 2002
29. Delgado R, Mikuz G, Hofstadter F. DNA-Feulgen-cytophotometric analysis of single cells isolated from paraffin embedded tissue. Pathol Res Pract 179:92-94, 1984
30. Goldstein NS, Qian J, Bostwick DG. Mucin expression in atypical adenomatous hyperplasia of the prostate. Hum Pathol 26:887-891, 1995
31. Epstein JI, Fynheer J. Acidic mucin in the prostate: Can it differentiate adenosis from adenocarcinoma? Hum Pathol 23:1321-1325, 1992
32. Ghazizadeh M, Sasaki Y, Oguro T, Aihara K. Silver staining of nucleolar organizer regions in prostatic lesions. Histopathology 19:369-372, 1991
33. Chastonay P, Hurlimann J, Gardiol D. Biological tissue markers in benign and malignant disease of the human prostate. Virchows Arch A Pathol Anat Histopathol 410:221-229, 1986
34. Berner A, Danielsen HE, Pettersen EO, Fossa SD, Reith A, Nesland JM. DNA distribution in the prostate. Normal gland, benign and premalignant lesions, and subsequent adenocarcinomas. Anal Quant Cytol Histol 15:247-252, 1993
35. Harper ME, Glynne-Jones E, Goddard L, Mathews P, Nicholson RI. Expression of androgen receptor and growth factors in premalignant lesions of the prostate. J Pathol 186:169-177, 1998
36. Brawer MK, Peehl DM, Stanley TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res 45:3663-3667, 1985
37. Shah IA, Schlageter MO, Stinnett P, Lechago J. Cytokeratin immunohistochemistry as a diagnostic tool for distinguishing malignant from benign epithelial lesions of the prostate. Mod Pathol 4:220-224, 1991